BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

925 related articles for article (PubMed ID: 19307067)

  • 1. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    Zietman AL; Shipley WU; Kaufman DS; Zehr EM; Heney NM; Althausen AF; McGovern FJ
    J Urol; 1998 Nov; 160(5):1673-7. PubMed ID: 9783929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
    Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
    Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer.
    Weiss C; Engehausen DG; Krause FS; Papadopoulos T; Dunst J; Sauer R; Rödel C
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1072-80. PubMed ID: 17467193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.
    Hussain MH; Glass TR; Forman J; Sakr W; Smith DC; Al-Sarraf M; Jones J; Balcerzak SP; Crawford ED; Grossman HB
    J Urol; 2001 Jan; 165(1):56-60; discussion 60-1. PubMed ID: 11125363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapidly alternating chemotherapy and radiotherapy instead of cystectomy for the treatment of muscle-invasive carcinoma of the urinary bladder: long term results of a pilot study.
    Vikram B; Chadha M; Malamud SC; Hecht H; Grabstald H
    Cancer; 1998 Mar; 82(5):918-22. PubMed ID: 9486582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
    Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
    Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intent-to-treat survival analysis.
    Koga F; Yoshida S; Kawakami S; Kageyama Y; Yokoyama M; Saito K; Fujii Y; Kobayashi T; Kihara K
    Urology; 2008 Aug; 72(2):384-8. PubMed ID: 18455771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ-sparing treatment in muscle-invasive bladder cancer.
    Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
    Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy.
    Chauvet B; Brewer Y; Félix-Faure C; Davin JL; Choquenet C; Reboul F
    J Urol; 1996 Oct; 156(4):1258-62. PubMed ID: 8808849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.
    Henry LR; Goldberg M; Scott W; Konski A; Meropol NJ; Freedman G; Weiner LM; Watts P; Beard M; McLaughlin S; Cheng JD
    Ann Surg Oncol; 2006 Feb; 13(2):214-20. PubMed ID: 16418887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
    Chauvet B; Félix-Faure C; Davin JL; Berger C; Vincent P; Reboul F
    Cancer Radiother; 1998 Apr; 2 Suppl 1():77s-81s. PubMed ID: 9749084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement.
    Chiang Y; Cheng JC; Huang CY; Tsai YC; Lin CC; Hsu CH; Cheng AL; Pu YS
    J Formos Med Assoc; 2017 Sep; 116(9):689-696. PubMed ID: 28034491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study.
    Koga F; Kihara K; Fujii Y; Yoshida S; Saito K; Masuda H; Kageyama Y; Kawakami S
    BJU Int; 2009 Jul; 104(2):189-94. PubMed ID: 19154452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle.
    Arias F; Dueñas M; Martínez E; Domínguez MA; Illarramendi JJ; Villafranca E; Tejedor M; Molina F; Meiriño R; Valerdi JJ
    Cancer; 1997 Jul; 80(1):115-20. PubMed ID: 9210716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.